<unk>  is a tyrosine kinase inhibitor that is FDA approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.   Common adverse reactions include diarrhea, rash, acne and dry skin.
Gefitinib
Nilotinib
Erlotinib
Lestaurtinib
Axitinib
Crizotinib
Afatinib
Sunitinib